Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIM: Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck
2017-003349-14Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Feb 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Nivolumab + ipilimumab with Docetaxel (2 arms). Primary endpoint: Objective response rate in all randomized patients. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-003349-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003349-14.